Access Resources
7351 - 7360 of 7616 Results
Title
Year
- Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations2010RESTRICTEDTitle: Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutationsJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 12Start Page: 1791End Page: 1800Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23221Best OA location URL: https://europepmc.org/articles/pmc6005705?pdf=renderCitation Count: 227
-
RESTRICTEDTitle: LRRK2 variation and Parkinson's disease in African AmericansJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 12Start Page: 1973End Page: 1976Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23163Best OA location URL: https://europepmc.org/articles/pmc2939165?pdf=renderCitation Count: 11
-
RESTRICTEDTitle: CSF Aβ42 and tau in Parkinson's disease with cognitive impairmentJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 15Start Page: 2682End Page: 2685Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23287Best OA location URL: https://europepmc.org/articles/pmc2978754?pdf=renderCitation Count: 163
-
RESTRICTEDTitle: LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson diseaseJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: 15Start Page: 2536End Page: 2541Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.23314Best OA location URL: https://europepmc.org/articles/pmc2978749?pdf=renderCitation Count: 62
- A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys2010RESTRICTEDTitle: A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeysJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 39Issue #: 3Start Page: 352End Page: 361Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.nbd.2010.05.001Citation Count: 143
- Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia2010RESTRICTEDTitle: Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementiaJournal Name: Experimental NeurologyPublisher: Elsevier BVVol: 225Issue #: 1Start Page: 210End Page: 218Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.expneurol.2010.06.017Best OA location URL: https://europepmc.org/articles/pmc2922478?pdf=renderCitation Count: 169
- Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS)2010RESTRICTEDTitle: Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS)Journal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 20Issue #: 17Start Page: 5175End Page: 5178Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2010.07.007Best OA location URL: https://europepmc.org/articles/pmc2922490?pdf=renderCitation Count: 26
-
RESTRICTEDTitle: Systemic Weakness After Therapeutic Injections of Botulinum Toxin AJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 33Issue #: 5Start Page: 243End Page: 247Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0b013e3181f5329eBest OA location URL: https://europepmc.org/articles/pmc3563356?pdf=renderCitation Count: 78
- 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization2010RESTRICTEDTitle: 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationJournal Name: Biochemical JournalPublisher: Portland Press Ltd.Vol: 430Issue #: 3Start Page: 393End Page: 404Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.1042/bj20100483Best OA location URL: https://portlandpress.com/biochemj/article-pdf/430/3/393/878058/bj4300393.pdfCitation Count: 353
- Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization2010RESTRICTEDTitle: Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localizationJournal Name: Biochemical JournalPublisher: Portland Press Ltd.Vol: 430Issue #: 3Start Page: 405End Page: 413Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1042/bj20100784Best OA location URL: https://portlandpress.com/biochemj/article-pdf/430/3/405/664434/bj4300405.pdfCitation Count: 352